Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone212-546-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$26.15 billion
Profitability
Miscellaneous
Employees23,300
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable
Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions
What is Bristol-Myers Squibb's stock symbol?
Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."
How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?
Bristol-Myers Squibb declared a quarterly dividend on Thursday, December 5th. Shareholders of record on Friday, January 3rd will be paid a dividend of $0.45 per share on Monday, February 3rd. This represents a $1.80 annualized dividend and a yield of 2.81%. The ex-dividend date is Thursday, January 2nd. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.41. View Bristol-Myers Squibb's Dividend History.
How were Bristol-Myers Squibb's earnings last quarter?
Bristol-Myers Squibb Co (NYSE:BMY) posted its quarterly earnings results on Thursday, February, 6th. The biopharmaceutical company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.88 by $0.34. The biopharmaceutical company had revenue of $7.95 billion for the quarter, compared to analyst estimates of $6.20 billion. Bristol-Myers Squibb had a net margin of 13.15% and a return on equity of 48.97%. Bristol-Myers Squibb's quarterly revenue was up 33.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.94 earnings per share. View Bristol-Myers Squibb's Earnings History.
When is Bristol-Myers Squibb's next earnings date?
What guidance has Bristol-Myers Squibb issued on next quarter's earnings?
Bristol-Myers Squibb issued an update on its FY20 earnings guidance on Thursday, February, 6th. The company provided EPS guidance of $6.00-$6.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.20. The company issued revenue guidance of $40.5-$42.50 billion, compared to the consensus revenue estimate of $42.21 billion.
What price target have analysts set for BMY?
14 brokers have issued 1 year price targets for Bristol-Myers Squibb's stock. Their forecasts range from $53.00 to $80.00. On average, they anticipate Bristol-Myers Squibb's stock price to reach $62.64 in the next year. This suggests that the stock has a possible downside of 2.1%. View Analyst Price Targets for Bristol-Myers Squibb.
What is the consensus analysts' recommendation for Bristol-Myers Squibb?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bristol-Myers Squibb.
Has Bristol-Myers Squibb been receiving favorable news coverage?
Media headlines about BMY stock have been trending very negative on Monday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Bristol-Myers Squibb earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Bristol-Myers Squibb.
Who are some of Bristol-Myers Squibb's key competitors?
Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).
What other stocks do shareholders of Bristol-Myers Squibb own?
Who are Bristol-Myers Squibb's key executives?
Bristol-Myers Squibb's management team includes the folowing people:
- Dr. Giovanni Caforio, Chairman & CEO (Age 54)
- Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
- Dr. Thomas J. Lynch Jr., Exec. VP & Chief Scientific Officer (Age 58)
- Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)
- Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57)
Who are Bristol-Myers Squibb's major shareholders?
Bristol-Myers Squibb's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wealth Quarterback LLC (6.76%), Charles Schwab Investment Management Inc. (1.21%), Loomis Sayles & Co. L P (0.84%), Capital World Investors (0.78%), Sumitomo Mitsui Trust Holdings Inc. (0.65%) and Franklin Resources Inc. (0.61%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, John E Elicker, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini and Theodore R Samuels II. View Institutional Ownership Trends for Bristol-Myers Squibb.
Which institutional investors are selling Bristol-Myers Squibb stock?
BMY stock was sold by a variety of institutional investors in the last quarter, including Baupost Group LLC MA, Franklin Resources Inc., MUFG Securities EMEA plc, Jacobs Levy Equity Management Inc., Barrow Hanley Mewhinney & Strauss LLC, Loomis Sayles & Co. L P, PGGM Investments and Alberta Investment Management Corp. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include John E Elicker, Karen Murphy Santiago and Louis S Schmukler. View Insider Buying and Selling for Bristol-Myers Squibb.
Which institutional investors are buying Bristol-Myers Squibb stock?
BMY stock was bought by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, TIG Advisors LLC, Charles Schwab Investment Management Inc., Prudential Financial Inc., Sumitomo Mitsui Trust Holdings Inc., Senator Investment Group LP, Swiss National Bank and California Public Employees Retirement System. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.
How do I buy shares of Bristol-Myers Squibb?
Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Bristol-Myers Squibb's stock price today?
One share of BMY stock can currently be purchased for approximately $63.97.
How big of a company is Bristol-Myers Squibb?
Bristol-Myers Squibb has a market capitalization of $104.23 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis. Bristol-Myers Squibb employs 23,300 workers across the globe.View Additional Information About Bristol-Myers Squibb.
What is Bristol-Myers Squibb's official website?
How can I contact Bristol-Myers Squibb?
Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]
MarketBeat Community Rating for Bristol-Myers Squibb (NYSE BMY)
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
